Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
69
CDTX Quote, Financials, Valuation and Earnings
Last price:
$221.38
Seasonality move
:
-15.48%
Day range:
$221.38 - $221.38
52-week range:
$15.22 - $221.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
55.23x
P/B ratio:
16.48x
Volume:
--
Avg. volume:
735K
1-year change:
941.79%
Market cap:
$7B
Revenue:
$1.3M
EPS (TTM):
-$11.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CDTX
Cidara Therapeutics, Inc.
|
-- | -$1.56 | -100% | -70.51% | $221.50 |
|
BMY
Bristol Myers Squibb Co.
|
$12.2B | $1.54 | -6.72% | 19.13% | $56.96 |
|
JNJ
Johnson & Johnson
|
$24.2B | $2.47 | 5.28% | -39.71% | $212.00 |
|
MRK
Merck & Co., Inc.
|
$16.2B | $2.03 | 1.82% | -62.58% | $113.48 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 2.06% | 43.22% | $28.66 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CDTX
Cidara Therapeutics, Inc.
|
$221.38 | $221.50 | $7B | -- | $0.00 | 0% | 55.23x |
|
BMY
Bristol Myers Squibb Co.
|
$55.26 | $56.96 | $112.5B | 18.66x | $0.63 | 4.51% | 2.35x |
|
JNJ
Johnson & Johnson
|
$218.66 | $212.00 | $526.8B | 21.10x | $1.30 | 2.35% | 5.75x |
|
MRK
Merck & Co., Inc.
|
$108.83 | $113.48 | $270.1B | 14.40x | $0.85 | 3.01% | 4.29x |
|
PFE
Pfizer Inc.
|
$25.65 | $28.66 | $145.8B | 14.95x | $0.43 | 6.71% | 2.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CDTX
Cidara Therapeutics, Inc.
|
0.47% | 4.188 | 0.07% | 4.47x |
|
BMY
Bristol Myers Squibb Co.
|
73.34% | -0.335 | 56.92% | 0.94x |
|
JNJ
Johnson & Johnson
|
36.62% | -0.032 | 10.26% | 0.71x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.108 | 20.79% | 1.06x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CDTX
Cidara Therapeutics, Inc.
|
-$28K | -$43.6M | -68.01% | -68.74% | -3675.83% | -$40.6M |
|
BMY
Bristol Myers Squibb Co.
|
$8.1B | $3.8B | 8.82% | 34.7% | 31.46% | $6B |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Cidara Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CDTX or BMY?
Bristol Myers Squibb Co. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 17.96%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.
Company Gross Margin Earnings Per Share Invested Capital CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M BMYBristol Myers Squibb Co.66% $1.08 $69.6B -
What do Analysts Say About CDTX or BMY?
Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $56.96 which suggests that it could grow by 3.07%. Given that Bristol Myers Squibb Co. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Bristol Myers Squibb Co. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CDTXCidara Therapeutics, Inc.0 3 0 BMYBristol Myers Squibb Co.5 17 1 -
Is CDTX or BMY More Risky?
Cidara Therapeutics, Inc. has a beta of 1.523, which suggesting that the stock is 52.269% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.215%.
-
Which is a Better Dividend Stock CDTX or BMY?
Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.51% to investors and pays a quarterly dividend of $0.63 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CDTX or BMY?
Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 18.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 2.35x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M BMYBristol Myers Squibb Co.2.35x 18.66x $12.2B $2.2B
-
Which has Higher Returns CDTX or JNJ?
Johnson & Johnson has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 21.47%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M JNJJohnson & Johnson69.72% $2.12 $125.1B -
What do Analysts Say About CDTX or JNJ?
Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could fall by -3.05%. Given that Cidara Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Cidara Therapeutics, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings CDTXCidara Therapeutics, Inc.0 3 0 JNJJohnson & Johnson9 11 0 -
Is CDTX or JNJ More Risky?
Cidara Therapeutics, Inc. has a beta of 1.523, which suggesting that the stock is 52.269% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.
-
Which is a Better Dividend Stock CDTX or JNJ?
Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.35% to investors and pays a quarterly dividend of $1.30 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CDTX or JNJ?
Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 5.75x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M JNJJohnson & Johnson5.75x 21.10x $24B $5.2B
-
Which has Higher Returns CDTX or MRK?
Merck & Co., Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 33.68%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About CDTX or MRK?
Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Merck & Co., Inc. has an analysts' consensus of $113.48 which suggests that it could grow by 4.27%. Given that Merck & Co., Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Merck & Co., Inc. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CDTXCidara Therapeutics, Inc.0 3 0 MRKMerck & Co., Inc.15 12 0 -
Is CDTX or MRK More Risky?
Cidara Therapeutics, Inc. has a beta of 1.523, which suggesting that the stock is 52.269% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.
-
Which is a Better Dividend Stock CDTX or MRK?
Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.01% to investors and pays a quarterly dividend of $0.85 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CDTX or MRK?
Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 4.29x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M MRKMerck & Co., Inc.4.29x 14.40x $17.2B $5.8B
-
Which has Higher Returns CDTX or PFE?
Pfizer Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 21.32%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About CDTX or PFE?
Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.05%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 11.72%. Given that Pfizer Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CDTXCidara Therapeutics, Inc.0 3 0 PFEPfizer Inc.7 15 1 -
Is CDTX or PFE More Risky?
Cidara Therapeutics, Inc. has a beta of 1.523, which suggesting that the stock is 52.269% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock CDTX or PFE?
Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios CDTX or PFE?
Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M PFEPfizer Inc.2.33x 14.95x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
